Key result
T2DM is linked to a ~108% higher risk of death or HF rehospitalization in post-PCI HFmrEF.
Why the study?
Data are limited on the effect of DM on the prognosis of ACS patients with HFmrEF who have undergone PCI.
Does Type 2 Diabetes Mellitus increase the risk of all-cause death or HF rehospitalization in ACS patients with HFmrEF who have undergone PCI?
Cohort (n=377)
No
Does Type 2 Diabetes Mellitus increase the risk of all-cause death or HF rehospitalization in ACS patients with HFmrEF who have undergone PCI?
Hazard Ratio: 2.08 (95% CI 1.115–3.878)
Absolute Event Rate: 96.1% vs 44.6%
p-value: p=0.021
Type 2 diabetes mellitus is a significant independent predictor of adverse long-term outcomes in patients with ACS and HFmrEF undergoing PCI.
DM associated with doubled composite risk post-PCI; extends diabetes prognostic data in ACS-HFmrEF but hypothesis-generating for targeted trials.
Background: Data are limited on the effect of diabetes mellitus (DM) on the prognosis of acute coronary syndrome (ACS) patients with heart failure with midrange ejection fraction (HFmrEF) who have undergone percutaneous coronary intervention (PCI). This study aimed to investigate the relationship between type 2 DM (T2DM) and 3-year outcomes in such a population. Methods: A total of 377 ACS patients with HFmrEF (left ventricular EF 40%– 49%) who had undergone PCI (132 diabetic and 245 nondiabetic patients) were included in the analysis. The primary outcome was a composite end point of all-cause death or HF rehospitalization. Cox proportional-hazard regression analysis and Kaplan–Meier tests were used to assess the effect of DM on the primary outcome. Sensitivity analysis was conducted with propensity score–matching analysis. Results: During a follow-up of 3 years, diabetic patients had higher incidence of the primary outcome than nondiabetic patients (96.1 vs 44.6 per 1,000 patient-years, incidence ratio 2.301, 95% CI 1.334– 3.969; P =0.002). Multivariate analysis showed that DM was associated with a significant increase in the composite outcome of all-cause death or HF rehospitalization (adjusted HR 2.080, 95% CI 1.115– 3.878; P =0.021). Sensitivity analysis further confirmed that DM was an independent prognostic factor of long-term adverse outcomes for ACS patients with HFmrEF who had undergone PCI (adjusted HR 3.792, 95% CI 1.802– 7.980; P < 0.001). Conclusion: Among ACS patients with HFmrEF who had undergone PCI, T2DM comorbidity was significantly associated with worse long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Li et al. (2021) conducted a cohort in Acute Coronary Syndrome with Heart Failure with Midrange Ejection Fraction (n=377). Type 2 Diabetes Mellitus vs. No Diabetes Mellitus was evaluated on Composite of all-cause death or HF rehospitalization (HR 2.080, 95% CI 1.115-3.878, p=0.021). Type 2 diabetes mellitus was associated with a significantly increased risk of the composite of all-cause death or heart failure rehospitalization (adjusted HR 2.080) in ACS patients with HFmrEF who underwent PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: